School of Medicine
Showing 41-50 of 95 Results
-
Tyler Johnson
Clinical Associate Professor, Medicine - Oncology
BioDr. Tyler Johnson--a clinical associate professor of medicine and oncology at Stanford University Medical School--is a physician, author, educator, and humanitarian. A medical oncologist, Dr. Johnson sees patients with all types of gastrointestinal malignancies and particularly focuses on patients with neuroendocrine tumors, colon cancer, and pancreas cancer.
Dr. Johnson served for many years as a leader of the Stanford Hospital in-patient oncology services and helped launch the hospital's first direct care inpatient service, med 12. He is also responsible for helping respond to the surge of patients that came with the pandemic and its aftermath.
Dr. Johnson views the practice of medicine largely as an educational endeavor. He directs the Stanford University Hematology/Oncology Fellowship Program and spends significant time teaching trainees at levels. To that end, for many years he has taught medical students, residents, and fellows—including hosting them as temporary and longer-term apprentices in his oncology clinic and working with them on the inpatient housestaff oncology service. He emphasizes diversity and inclusion in his mentoring efforts and has worked to promote the professional development of medical trainees across the training spectrum--from undergraduates to oncology fellows.
The winner of multiple Stanford Medicine teaching awards, Dr. Johnson has established himself as a regional and increasingly as a national leader and innovator in the education of oncology fellows, including by developing novel teaching methods that have been presented across the country, including at national meetings. He also works as one of the principal faculty members of the Stanford Educators-4-CARE program.
Dr. Johnson and his co-host, Henry Bair, became concerned about the loss of a shared sense of meaning in the medical profession and, together, have taught multiple classes in the Medical School and, in the spring of 2022, founded The Doctor's Art podcast. Since then, the podcast has become one of the most listened to medical podcasts in the world and has won multiple national awards, making it one of the most lauded and most popular medical podcasts.
Finally, Dr. Johnson is an author with a growing reputation for insightful analysis of the intersection of medicine, ethics, and spirituality. His writings has been featured by Religion News Service, the Salt Lake Tribune, BYU Studies, Dialogue, and The San Jose Mercury News, where he is a regular contributor. He serves on the editorial boards of both BYU Studies and Wayfare and has written extensively on modernity loss of faith and meaning and the role of spirituality in constructing a purposeful and fulfilling life. -
Maximilian Julve
Clinical Assistant Professor, Medicine - Oncology
BioDr. Max Julve is a medical oncologist and Clinical Assistant Professor of Medicine (Oncology) at Stanford University School of Medicine, with a clinical and research focus in solid tumor cellular therapy and melanoma.
Dr. Julve completed his medical training at Barts and The Royal London School of Medicine in the United Kingdom, followed by internal medicine training at teaching hospitals across North and Central London. He was subsequently awarded a National Institute for Health and Care Research (NIHR) Academic Clinical Fellowship in Medical Oncology at Imperial College London. During this time, alongside his clinical training, he conducted translational research within the King’s College London Immunoengineering group, focusing on transcriptional optimization of CAR-T cell therapies.
Dr. Julve later completed advanced clinical fellowships in solid tumor cellular therapy and melanoma at The Royal Marsden Hospital, London, and earned an MD(Res) doctorate investigating the role of immunosuppressive granulocytes in patients receiving immunotherapy.
He is a clinical investigator specializing in melanoma, immuno-oncology, and solid tumor cellular therapy, with a particular emphasis on translating mechanistic insights from the laboratory into novel therapeutic strategies for patients. -
Hyunseok Kang
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research interest lies in development of precision oncology based approaches and novel therapeutics for rare cancers of head and neck, including adenoid cystic cancers, salivary duct cancers, sinonasal cancers and thyroid cancers.
-
Ali Raza Khaki, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Khaki is a medical oncologist and clinical assistant professor at Stanford University School of Medicine.
In his clinical practice, he treats patients with all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. He also regularly attends on the inpatient oncology service at Stanford Hospital.
With each patient, he is devoted to providing exceptional, humanistic care and has been recognized throughout his career for his humanism. As a medical student, he was named to the national Gold Humanism Honor Society and he received the Reza Gandjei Humanism Award as a medical resident at UCSF.
His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He is the site principal investigator for multiple clinical trails investigating new therapies for genitourinary cancers.
Dr. Khaki is also active working clinically in inpatient oncology and is a Unit Based Medical Director for G1, an oncology hospital unit and is the Director of Inpatient Oncology. In this role, he oversees the inpatient oncology teams, works closely with the cancer center to develop new transitions of care pathways from inpatient to outpatient and has co-led an inpatient oncology research group to study quality improvement, care delivery and end-of-life care for patients with cancer.
Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.
He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. In addition, he is an editor for HemOnc.org and theMednet, a physician-only online community where members share clinical questions and answers. -
Saad A. Khan, MD
Associate Professor of Medicine (Oncology)
BioDr. Khan is a fellowship-trained cancer specialist with board certification in oncology and hematology. He is an assistant professor in the Department of Medicine, Division of Oncology.
Dr. Khan focuses on the treatment of head and neck cancers, advanced thyroid cancers, and neuroendocrine tumors. He recognizes the broad effects of these conditions on daily living and aims to develop personalized, comprehensive treatment plans that optimize health and quality of life.
Dr. Khan’s research interests include therapeutic clinical trials as well as ways to reduce toxicities that some patients may experience when receiving cancer treatment. His research activities include ongoing clinical trials of targeted and immune therapy for aggressive thyroid cancer.
He has published numerous articles on his research discoveries in peer-reviewed journals such as the JAMA Oncology, Investigational New Drugs, and others. Topics include new drug treatments for small cell lung cancer and for cancers of the head and neck, racial and gender disparities in certain types of cancer, and management of the potentially toxic effects of cancer therapies.
Dr. Khan is a member of the NRG Head and Neck Committee. NRG brings together internationally recognized groups (the first words in their names form the acronym “NRG”) to conduct cancer clinical research and share study results. The objective is to inform clinical decision making and healthcare policy worldwide.
Dr. Khan is a member of the ECOG Head and Neck Core and Thoracic Committees. ECOG (Eastern Cooperative Oncology Group) is part of one of the five groups of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Program.
He also is a member of the National Cancer Institute’s Central IRB for Early Phase Clinical Trials.
When not providing patient care or conducting research, Dr. Khan enjoys spending time with his family, hiking, and relaxing at the beach. -
Youn H Kim, MD
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Current Research and Scholarly InterestsClinical research in cutaneous lymphomas, especially, mycosis fungoides; studies of prognostic factors, long-term survival results, and effects of therapies. Collaborative research with Departments of Pathology and Oncology in basic mechanisms of cutaneous lymphomas. Clinical trials of new investigative therapies for various dermatologic conditions or clinical trials of known therapies for new indications.
-
Allison W. Kurian, M.D., M.Sc.
Professor of Medicine (Oncology) and of Epidemiology and Population Health
Current Research and Scholarly InterestsI aim to understand cancer burden and improve treatment quality at the population level. I have a strong focus on genetic risk assessment and precision oncology. I lead epidemiologic studies of cancer risk factors, clinical trials of novel approaches to cancer risk reduction, and decision analyses of strategies to optimize cancer outcomes.
-
David Kurtz
Adjunct Clinical Assistant Professor, Medicine - Oncology
Current Research and Scholarly InterestsImplementation of noninvasive detection of malignancies in the clinic remains difficult due to both technical and clinical challenges. These include necessary improvements in sensitivity and specificity of biomarkers, as well as demonstration of clinical utility of these assays. My research focuses on technical development and implementation of assays to detect and track cancers in order to facilitate personalized disease management.
-
Sheila Lahijani, MD, FACLP
Clinical Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry
Clinical Professor (By courtesy), Medicine - OncologyBioDr. Lahijani is a Clinical Professor of Medical Psychiatry and, by courtesy, Oncology, at Stanford University School of Medicine and a nationally recognized leader in psycho-oncology. With extensive training and expertise in internal medicine, psychiatry, and consultation-liaison psychiatry, she has made significant contributions to the integration of psychiatric care within oncological settings.
Since her appointment at Stanford in 2015, Dr. Lahijani has served as the lead psychiatric oncologist at the Stanford Cancer Center, where she provides medical psychiatric consultation services and collaborates with interdisciplinary teams to enhance patient outcomes. In her capacity as Medical Director of the Stanford Cancer Center Psychosocial Oncology Program, a position she has held since 2019, she is responsible for the strategic development and implementation of comprehensive psychiatric services tailored to the unique needs of patients with cancer.
Additionally, Dr. Lahijani serves as the Section Chief of Psycho-Oncology in the Division of Medical Psychiatry where she oversees psych-onc faculty development and leads the training of medical psychiatry fellows in psycho-oncology. She also supervises advanced practice providers while also working as an attending psychiatric oncologist to provide care for patients with complex medical and psychiatric comorbidities across all hematology and oncology units.
Dr. Lahijani's academic credentials include her graduation from Brown Medical School, followed by the completion of a combined residency in Internal Medicine and Psychiatry at Rush University Medical Center. After completing residency, she practiced internal medicine and psychiatry with a focus on triple diagnosis (HIV, addiction medicine, mental health). She then further advanced through a Psychosomatic Medicine Fellowship at Northwestern University's Feinberg School of Medicine, during which time she received specialized training in psychiatric oncology at the Lurie Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.
Her clinical expertise encompasses psychopharmacology and a range of treatment modalities, including Meaning Centered Psychotherapy and Dignity Therapy. Dr. Lahijani is deeply committed to fostering relationship-centered skills and promoting provider wellness. As a faculty member of Advancing Communication Excellence at Stanford, she has led workshops designed to enhance communication competencies among faculty and staff.
Dr. Lahijani's scholarly pursuits are at the intersection of medicine and psychiatry, with a particular emphasis on the neuropsychiatric sequelae of cancer treatment, innovations in care, and medical education. She is dedicated to the education and mentorship of trainees in Psychiatry, Internal Medicine, Hematology/Oncology, and Neurology. Through her commitment to academic excellence, Dr. Lahijani plays a pivotal role in preparing the next generation of healthcare providers to adeptly navigate the intricate and multifaceted needs of patients and their caregivers, thereby promoting a comprehensive approach to patient care.
